Legal & regulatory status
No drug regulator in this course's source record has approved Melanotan II for any use, and several have warned…
Unapproved, warned against, and still sold: the regulatory reality
No drug regulator in this course's source record has approved Melanotan II for any use, and several have warned consumers against it, removed its listings, and acted against its supply. Yet it remains widely available online behind a "research chemical" label. This unit maps that contradiction: what each regulator actually said, the legal fiction that sustains the market, and the unregulated-supply risks that follow.
Read every entry as a quotation rather than a finding. A regulator's warning is what the regulator said, published to protect consumers, not an incidence table and not a causal assessment.
Key terms
The worldwide status
Across every jurisdiction with a fetched record, the verdict on MT-II is the same: not approved. The agencies differ in wording and enforcement, and each entry below is what that agency said in its own document, on a stated date. Tap each jurisdiction to see its specific stance.
What every entry shares is an absence of approval, not a single shared verdict, and the wording differs for good reason. Note the recurring confusion the sources themselves fall into: the approval of afamelanotide (Melanotan I), a different linear peptide for a rare light-sensitivity disease, does not extend to MT-II, and neither does the approval of bremelanotide. No fetched source gives an EU-wide or EMA determination on melanotan II either, so this course asserts none.
AdvancedWhy MT-I being approved does not help MT-II
Afamelanotide (Melanotan I) is approved as SCENESSE for a rare light-sensitivity disease: a linear thirteen-residue peptide delivered as an implant, and described in the dermatology literature as the only alpha-MSH analogue approved for a limited number of medical indications. MT-II is a different compound, a cyclic heptapeptide, non-selective, unstudied at scale, and sold without quality control. Regulators approve molecules and indications, not names, so the SCENESSE approval gives MT-II no legal or scientific cover whatsoever. The same applies in reverse: nothing in the approved product's trials, label or safety profile describes melanotan II.